Antihormones in prevention and treatment of breast cancer (Q36721743)

15 August 2017

1 reference

title

Antihormones in prevention and treatment of breast cancer (English)

1 reference

15 August 2017

Riccardo Ponzone

1

1 reference

15 August 2017

Nicoletta Biglia

2

1 reference

15 August 2017

Maria Elena Jacomuzzi

3

1 reference

15 August 2017

Luca Mariani

4

1 reference

15 August 2017

Annelise Dominguez

5

1 reference

15 August 2017

Piero Sismondi

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Annals of the New York Academy of Sciences

15 August 2017

1 reference

15 August 2017

1089

1 reference

15 August 2017

143-158

1 reference

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

15 August 2017

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Adjuvant endocrine therapy for premenopausal women with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1386.037

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1386.037

1 reference

15 August 2017

1 reference